CHF Solutions Webinar Highlighted Importance of Fluid Management in Patients Treated for COVID-19
March 18 2020 - 8:00AM
CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to
improving the lives of patients suffering from fluid overload,
announced the key takeaways from its clinician webinar held
yesterday, which stressed the importance of managing fluids
administered to critically ill, COVID-19 patients to avoid
potentially life-threatening complications.
Because COVID-19 patients are hemodynamically unstable, they
need fluid replacement, which puts them at risk for developing
volume overload, acute respiratory distress syndrome (ARDS), and
other complications related to progressive congestion.
The medical panel unanimously agreed that fluid stewardship is
very important in patients with COVID-19 who become critically ill,
and that ultrafiltration is an option for efficient fluid removal
and rapid decongestion, and a way to optimize the volume status of
these patients in a predictable way.
The physicians described the many benefits that portable
ultrafiltration devices, like CHF Systems’ Aquadex SmartFlow™, have
over conventional renal replacement therapies, such as ease of use,
and the speed with which therapy can be initiated in the ICU.
They also cited the low extracorporeal volume (35 mL) for patients
with hemodynamic instability, and the low blood flow rate, which is
not achievable with conventional dialysis machines.
The webinar panel was moderated by Dr. Amir Kazory, M.D., FASN
(University of Florida, Gainesville), with Dr. Maria DeVita, M.D.,
FACP, FASN (Lenox Hill Hospital, NY, NY) and Dr. Mehdi Oloomi, M.D.
(Mount Sinai Medical Center) serving as panelists.
The learning objectives for the webinar were:
- Discuss the World Health Organization (WHO) protocol, published
March 13, 2020, and the importance of identifying volume overload
in COVID-19-infected patients because the risk of volume overload
is very high1
- Understand the risks associated with volume overload,
importance of maintaining fluid balance, and benefits of using
ultrafiltration in patients with volume overload
- Discuss training and personnel required to quickly implement
access to ultrafiltration
- Listen to real-world critical care patient case studies
“We are pleased that the three physician panelists, who are
experienced users of ultrafiltration technology in the critical
care setting, were able to present a valuable solution for the
treatment of critically ill COVID-19 patients,” said John Erb, CEO
of CHF Solutions. "The Aquadex SmartFlow system is designed to
address the needs of critical care patients suffering from
hypervolemia (volume overload) and we want to ensure that all
patients are able to access this therapy.”
An audio replay of the webcast, slides and a transcript are
available at http://ir.chf-solutions.com/events.
About CHF Solutions CHF Solutions, Inc.
(Nasdaq: CHFS) is a medical device company dedicated to improving
the lives of patients suffering from fluid overload with its novel
ultrafiltration therapy system. The company is focused on
developing, manufacturing and commercializing the Aquadex SmartFlow
system for ultrafiltration therapy. CHF Solutions is headquartered
in Minneapolis, Minn., with wholly-owned subsidiaries in Australia
and Ireland. The company has been listed on the Nasdaq Capital
Market since February 2012.
About the Aquadex SmartFlow System The Aquadex
SmartFlow system delivers clinically proven therapy using a simple,
flexible and smart method of removing excess fluid from patients
suffering from hypervolemia (fluid overload). The Aquadex SmartFlow
system is indicated for temporary (up to 8 hours) or extended
(longer than 8 hours in patients who require hospitalization) use
in adult and pediatric patients weighing 20 kg or more whose fluid
overload is unresponsive to medical management, including
diuretics. All treatments must be administered by a health care
provider, within an outpatient or inpatient clinical setting, under
physician prescription, both having received training in
extracorporeal therapies.
Forward-Looking Statements Certain statements
in this release may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation, statements about the clinical
use of the Aquadex SmartFlow system in patients infected with
COVID-19. Forward-looking statements are predictions, projections
and other statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our ability to execute on our commercial strategy, the possibility
that we may be unable to raise sufficient funds necessary for our
anticipated operations, our post-market clinical data collection
activities, benefits of our products to patients, our expectations
with respect to product development and commercialization efforts,
our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, intellectual
property protection, our ability to integrate acquired businesses,
our expectations regarding anticipated synergies with and benefits
from acquired businesses, and other risks and uncertainties
described in our filings with the SEC. Forward-looking statements
speak only as of the date when made. CHF Solutions does not assume
any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
1 WHO reference number: WHO/nCoV/Clinical/2020.3
CONTACTS
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer, CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
MEDIA:
Brad Perriello
Health+Commerce
617-817-1385
brad@healthandcommerce.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2024 to May 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From May 2023 to May 2024